Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−59.50 M USD
0.00 USD
53.25 M
About Connect Biopharma Holdings Limited
Sector
CEO
Barry D. Quart
Headquarters
Taicang
Website
Founded
2015
FIGI
BBG00ZGYNJ49
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.